SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immatics Presents Clinical Activity Data for Two PRAME Therapies

Immatics presented clinical activity data for its IMA402 bispecific and IMA203CD8 cell therapy in two oral presentations.

IMTX

Related stories